Design Therapeutics appoints David Shapiro to board of directors

Design Therapeutics Inc. (NASDAQ: DSGN) appointed David Shapiro, M.D., to its board of directors as a Class III director, effective March 31, 2026. His term will end at the company's 2027 annual meeting of stockholders.

Shapiro was also appointed to serve on the company's Nominating and Corporate Governance Committee.

Under the company's non-employee director compensation policy, Shapiro will receive an annual cash retainer of $40,000 for board service and $5,000 for committee membership. He received an initial stock option grant to purchase 60,000 shares of common stock, which vests monthly over three years, and a prorated annual option grant for 7,500 shares, vesting monthly over one year.

The company and Shapiro entered into a standard indemnification agreement for directors and officers, according to a company statement.

You May Also Be Interested In

• Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
• Barclays Downgrades Brown Forman (BF-B) to Equalweight
• RBC Capital Starts VICI Properties Inc. (VICI) at Sector Perform